mapo/iStock through Getty Pictures
- Rapport Therapeutics (RAPP), backed by the enterprise capital arm of Johnson & Johnson (JNJ), on Thursday introduced the pricing of its preliminary public providing of 8M shares of its frequent inventory at a public providing value of $17.00 per share.
- The gross proceeds to Rapport (RAPP) from the preliminary public providing and the concurrent non-public placement, are anticipated to be roughly $154 million.
- Rapport’s (RAPP) shares are anticipated to start buying and selling on the Nasdaq International Market on June 7, underneath the ticker image “RAPP.”
- The providing is anticipated to shut on June 10.
- Supply: Press Launch
